miltefosine has been researched along with Cholera Infantum in 5 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Miltefosine is a phosphocholine analogue that affects cell-signaling pathways and membrane synthesis." | 2.69 | Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. ( Bachmann, P; Berman, J; Fischer, C; Jha, TK; Karbwang, J; Sundar, S; Thakur, CP; Voss, A, 1999) |
| "The toxic effects of miltefosine on the epithelial cells of the gastrointestinal tract and its hemolytic action on erythrocytes have limited its use as an antileishmanial agent." | 1.43 | Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages. ( Barioni, MB; da Gama Bitencourt, JJ; de Paula Pinto, C; Guimarães, TH; Ito, AS; Pazin, WM; Santos, MA; Santos, MR; Valduga, CJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| da Gama Bitencourt, JJ | 1 |
| Pazin, WM | 1 |
| Ito, AS | 1 |
| Barioni, MB | 1 |
| de Paula Pinto, C | 1 |
| Santos, MA | 1 |
| Guimarães, TH | 1 |
| Santos, MR | 1 |
| Valduga, CJ | 1 |
| Sundar, S | 3 |
| Sinha, PK | 2 |
| Verma, DK | 1 |
| Kumar, N | 2 |
| Alam, S | 1 |
| Pandey, K | 2 |
| Kumari, P | 1 |
| Ravidas, V | 1 |
| Chakravarty, J | 1 |
| Verma, N | 2 |
| Berman, J | 2 |
| Ghalib, H | 1 |
| Arana, B | 1 |
| Bhattacharya, SK | 1 |
| Thakur, CP | 2 |
| Jha, TK | 2 |
| Das, VR | 1 |
| Lal, C | 1 |
| Singh, VP | 1 |
| Ranjan, A | 1 |
| Verma, RB | 1 |
| Anders, G | 1 |
| Sindermann, H | 1 |
| Ganguly, NK | 1 |
| Bachmann, P | 1 |
| Karbwang, J | 1 |
| Fischer, C | 1 |
| Voss, A | 1 |
| Herwaldt, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India[NCT00371995] | Phase 2 | 150 participants (Anticipated) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for miltefosine and Cholera Infantum
| Article | Year |
|---|---|
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiprotozoal Agents; Aspartate | 2007 |
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Aspartate Aminotransferases; Female; | 1999 |
3 other studies available for miltefosine and Cholera Infantum
| Article | Year |
|---|---|
Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages.
Topics: Animals; Antiprotozoal Agents; Cell Death; Cells, Cultured; Drug Carriers; Drug Stability; Erythrocy | 2016 |
Ambisome plus miltefosine for Indian patients with kala-azar.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Child; Child, P | 2011 |
Miltefosine--the long-awaited therapy for visceral leishmaniasis?
Topics: Administration, Oral; Antiprotozoal Agents; Female; Gastrointestinal Diseases; Humans; Leishmaniasis | 1999 |